Certara (CERT) to Release Quarterly Earnings on Wednesday

Certara (NASDAQ:CERT) is set to post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Certara to post earnings of $0.11 per share for the quarter. Certara has set its FY24 guidance at $0.41 to $0.46 EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Certara (NASDAQ:CERT) last posted its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $93.31 million for the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business’s revenue was up 3.2% on a year-over-year basis. During the same period last year, the company posted $0.10 EPS. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Certara Stock Performance

Certara stock opened at $10.35 on Wednesday. The firm’s 50 day simple moving average is $11.39 and its 200 day simple moving average is $14.00. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.67 billion, a PE ratio of -20.70, a price-to-earnings-growth ratio of 5.40 and a beta of 1.49. Certara has a 1-year low of $9.99 and a 1-year high of $19.87.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. Robert W. Baird decreased their price target on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. KeyCorp decreased their price target on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Barclays decreased their price target on shares of Certara from $16.00 to $14.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 15th. Finally, UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.08.

Insider Activity

In other news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Certara news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by corporate insiders.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.